natgillin/translations-raw huggingface dataset:
Plasma exposures to ivacaftor in rats at the non-carcinogenic dosage (50 mg/kg/day, the highest dosage tested) were approximately 17- to 31-fold higher than the exposure measured in humans following ivacaftor therapy.
Izloženost štakora ivakaftoru u plazmi pri nekancerogenim dozama (50 mg/kg na dan, najviša ispitana doza) bila je približno 17 do 31 puta veća od izloženosti izmjerene u ljudi nakon terapije ivakaftorom.
Plasma HCV -RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory
HCV-RNK u plazmi mjerila se istraživanjem utemeljenim postupkom kvantitativne lančane reakcije polimeraze u centralnom laboratoriju.
Plasma HCV RNA values were measured during the clinical trials using the COBAS TaqMan HCV test (version 2.0), for use with the High Pure System.
Vrijednosti HCV RNK u plazmi mjerene su tijekom kliničkih ispitivanja COBAS TaqMan HCV testom (verzija 2.0), namijenjenim za uporabu sa sustavom High Pure System.
Plasma HCV-RNA is measured with a research-based quantitative polymerase chain reaction assay by a central laboratory
HCV-RNK u plazmi mjerila se na istraživanju utemeljenim postupkom kvantitativne lančane reakcije polimerazom u centralnom laboratoriju.
Plasma HIV-1 RNA
HIV-1 RNK u plazmi
Plasma HIV-RNA
HIV-RNK u plazmi
Plasma level monitoring in a Phase III clinical study showed that levels of total silodosin after 4 weeks of treatment did not change in patients with mild impairment (n=70), compared to patients with normal renal function (n=155), while the levels were doubled on average in patients with moderate impairment (n=7).
Praćenje razine u plazmi u fazi III kliničkog ispitivanja pokazalo je da se razine ukupnog silodozina nakon 4 tjedna liječenja nisu promijenile u bolesnika s blagim oštećenjem funkcije bubrega (n=70) u usporedbi s bolesnicima s normalnom funkcijom bubrega (n=155), dok su razine u prosjeku bile udvostručene u bolesnika s umjerenim oštećenjem funkcije bubrega (n=7).
plasma levels is not known.
klaritromicina u plazmi nije
Plasma levels of 3- OMD were markedly and dose-dependently decreased by tolcapone when given with levodopa/AADC-I (aromatic amino acid decarboxylase - inhibitor) (benserazide or carbidopa).
Tolkapon je značajno i ovisno o dozi smanjio plazmatske razine 3-OMD-a kada se davao s levodopom/AADC-I (inhibitor dekarboksilaze aromatske aminokiseline) (benzerazid ili karbidopa).
Plasma levels of carglumic acid were measured in patients of all age categories, from newborn infants to adolescents, treated with various daily doses (7 – 122 mg/kg/day).
Razina karglumatne kiseline u plazmi izmjerena je kod bolesnika svih dobnih skupina, od novorođenčadi do adolescenata, liječenih raznim dnevnim dozama (7 – 122 mg/kg/dan).
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by co-administration with Clomicalm.
Plazmatske razine određenih antiepileptika, poput fenitoina i karbamazepina, mogu se povisiti uz istodobnu primjenu Clomicalma.
Plasma levels of certain anti- epileptic drugs, such as phenytoin and carbamazepine, may be increased by coadministration with Clomicalm.
Plazmatske razine određenih antiepileptika, poput fenitoina i karbamazepina, mogu se povisiti uz istodobnu primjenu Clomicalma.
Plasma levels of doxorubicin and its metabolite, doxorubicinol, may be increased when doxorubicin is administered with cyclosporin, verapamil, paclitaxel or other agents that inhibit P-glycoprotein (P-Gp).
Plazmatske razine doksorubicina i njegovog metabolita, doksorubicinola mogu biti povećane kad se doksorubicin primjenjuje s ciklosporinom, verapamilom, paklitakselom ili drugim lijekovima koji inhibiraju P-glikoprotein (P-Gp).
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug metabolising enzymes and/or transport proteins by St. John’s wort.
Koncentracija efavirenza u plazmi može se smanjiti zbog istodobne primjene gospine trave zato što gospina trava izaziva indukciju enzima koji metaboliziraju lijek i/ili transportnih proteina.
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug metabolising enzymes and/or transport proteins by St. John’s wort.
Razine efavirenza u plazmi mogu biti snižene u slučaju istodobnog uzimanja gospine trave jer ona inducira enzime koji metaboliziraju lijek i/ili transportne proteine.
Plasma levels of efavirenz can be reduced by concomitant use of St. John’s wort due to induction of drug-metabolising enzymes and/or transport proteins by St. John’s wort.
Koncentracija efavirenza u plazmi može se smanjiti zbog istodobne primjene gospine trave, jer ista inducira enzime koji metaboliziraju lijek i/ili transportne proteine.
Plasma levels of these metabolites detected after administration of Fortacin in clinical trials were low in both male and female subjects, even after doses of it many times in excess of the clinical dose were applied.
Razine tih metabolita u plazmi utvrđenih nakon primjene lijeka Fortacin pri kliničkim ispitivanjima bile su niske i u muških i u ženskih osoba, čak i kada su primjenjivane doze višestruko veće od terapijske kliničke doze.
Plasma levels readily declined with mean t½ values ranging from 4.6 to 5.7 hours on day 1 and from 5.1 to 10.1 hours on day 21.
Razine u plazmi su se smanjile s vrijednostima t½ od 4,6 do 5,7 sati na dan 1 i od 5,1 do 10,1 sati na 21dan.
Plasma migalastat exposure (AUC0-∞) and Cmax demonstrated dose-proportional increases at migalastat oral doses from 50 mg to 1,250 mg.
Izloženost migalastatu u plazmi (AUC0-∞) i Cmax pokazali su povećanje proporcionalno dozi pri oralnim dozama migalastata od 50 mg do 1250 mg.
Plasma pharmacokinetic profiles were analysed on day 1 and on either day 7 or day 28, by which time plasma concentrations had reached steady state.
Farmakokinetički profili u plazmi analizirani su na 1. dan te ili 7. dan ili na 28. dan, a do toga su vremena koncentracije u plazmi postigle stanje dinamičke ravnoteže.
Plasma potassium level must be closely monitored in patients at risk of hyperkalaemia.
Treba pažljivo kontrolirati razinu kalija u pacijenata s rizikom od razvoja hiperkalemije.
Plasma potassium should be measured in patients at risk before starting heparin therapy and monitored regularly thereafter particularly if treatment is prolonged beyond about 7 days.
U bolesnika kod kojih postoji ovaj rizik potrebno je izmjeriti razinu kalija u plazmi prije započinjanja liječenja heparinom i nakon toga redovito je pratiti, osobito ako je liječenje produženo više od 7 dana.
Plasma protein binding
Vezanje za proteine u plazmi
Plasma protein binding could not be measured due to instability, but based on the physicochemical properties of osimertinib plasma protein binding is likely to be high.
Vezanje na proteine u plazmi nije se moglo izmjeriti zbog nestabilnosti, ali s obzirom na fizikalno-kemijska svojstva osimertiniba vjerojatno je da je vezanje na proteine u plazmi visoko.
Plasma protein binding following a single oral dose of 14C-labelled rasagiline is approximately 60 to 70%.
Vezanje za proteine plazme nakon pojedinačne oralne doze 14C-obilježenog razagilina je približno 60 do 70 %.
Plasma protein binding following a single oral dose of 14C-labelled rasagiline is approximately 60 to 70%.
Vezanje za proteine plazme nakon pojedinačne oralne doze 14C-obilježenog razagilina je približno 60 do 70%.
Plasma protein binding in humans is high at approximately 92 % to 95 %, with serum albumin being the main binding component.
Stupanj vezanja na proteine plazme u ljudi je visok, oko 92 % do 95 %, pri čemu je glavna komponenta na koju se veže serumski albumin.
Plasma protein binding in humans is high at approximately 92 % to 95 %, with serum albumin being the main binding component.
Stupanj vezanja na proteine u plazmi u ljudi je visok, oko 92 % do 95 %, pri čemu je glavna komponenta na koju se veže serumski albumin.
Plasma protein binding in humans is high at approximately 95%, with serum albumin and alpha 1- acidic glycoprotein being the main binding components.
Vezanje za proteine plazme u ljudi je visoko i iznosi približno 95%, s time da su serumski albumin i alfa 1-kiseli glikoprotein glavne komponente za koje se veže.
Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
Vezanje za proteine u plazmi nije značajno izmijenjeno u bolesnika s oštećenjem bubrežne ili jetrene funkcije.
Plasma protein binding is not meaningfully altered in subjects with renal or hepatic impairment.
Vezanje za proteine u plazmi nije značajno izmijenjeno u ispitanika s oštećenjem bubrežne ili jetrene funkcije.
Plasma protein binding of decitabine is negligible (< 1%).
Vezanje decitabina na proteine plazme zanemarivo je (<1%).
Plasma protein binding of irbesartan is approximately 96 %, with negligible binding to cellular blood components.
Oko 96% irbesartana veže se za proteine u plazmi, sa zanemarivim vezanjem za krvne stanice.
Plasma protein binding of the active metabolite is low with approximately 50% bound to albumin and alpha-1-acid glycoprotein.
Vezanje djelatnog metabolita za proteine plazme je nisko: približno 50% vezano je za albumin i alfa- 1-kiseli glikoprotein.
Plasma protein binding of varenicline is low (< 20%) and independent of both age and renal function.
Stupanj vezanja vareniklina za proteine u plazmi je nizak (≤ 20%), a ne ovisi ni o dobi ni o bubrežnoj funkciji.
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~ 49 %) to human plasma proteins at therapeutic concentrations.
Ispitivanja o vezanju na proteine plazme in vitro pokazuju da se abakavir u terapijskim koncentracijama veže slabo do umjereno ( 49%) na proteine ljudske plazme.
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.
Ispitivanja o vezanju na proteine plazme in vitro pokazuju da se abakavir u terapijskim koncentracijama veže slabo do umjereno (49%) na proteine ljudske plazme.
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.
Ispitivanja vezivanja za proteine u plazmi in vitro pokazuju da se abakavir u terapijskim koncentracijama tek malo do umjereno vezuje za proteine u plazmi ljudi (~49%).
Plasma protein binding studies in vitro indicate that abacavir binds only low to moderately (~49%) to human plasma proteins at therapeutic concentrations.
Studije o vezanju na proteine plazme in vitro pokazuju da se abakavir u terapijskim koncentracijama veže slabo do umjereno (49%) na ljudske proteine plazme.
Plasma protein binding was low, approximately 40%.The volume of distribution at steady-state (VSS) determined after intravenous administration was 13.2 l/kg.
Volumen raspodjele u ravnoteži (Vss) utvrđen nakon intravenske primjene bio je 13,2 l/kg.
Plasma salicylate concentrations above 300 mg/l (1.67 mmol/l) suggest intoxication.
Koncentracija salicilata u plazmi iznad 300 mg/l (1,67 mmol/l) upućuje na intoksikaciju.
Plasma trough
Najniže koncentracije lijeka
Plasma trough concentrations of boceprevir were decreased when administered with efavirenz, a component of Atripla.
Najniže koncentracije boceprevira u plazmi bile su snižene kad se primjenjivao s efavirenzom, sastojkom Atriple.
Plasma trough levels of insulin glargine and its main M1 and M2 metabolites were measured in children treated with insulin glargine, revealing plasma concentration patterns similar to adults, and providing no evidence for accumulation of insulin glargine or its metabolites with chronic dosing.
Mjerenje najniže razine inzulina glargina i njegovih glavnih metabolita M1 i M2 u djece liječene inzulinom glarginom otkrilo je da su obrasci koncentracija u plazmi slični kao u odraslih te nije bilo dokaza o kumulaciji inzulina glargina ni njegovih metabolita pri dugotrajnoj primjeni.
Plasma Uric Acid < 6 mg/dl for at Least 80% of the Time During Months 3 and 6
Plazmatske razine mokraćne kiseline <6 mg/dl najmanje 80% vremena tijekom 3. i
plaster(s) gauze pad(s).
flaster(e) kompresu(e) od gaze
Plaster.
Flaster.
Plastic (HDPE) bottle with child resistant plastic (PP) closure packaged into an outer cardboard box.
Plastične (HDPE) bočice sa sigurnosnim zatvaračem od plastike (PP) kojega ne mogu otvoriti djeca, pakirane u vanjsku kartonsku kutiju.
PLASTIC BAG
PLASTIČNA VREĆICA
PLASTIC BAG (TERTIARY)
PLASTIČNA VREĆICA (TERCIJARNA AMBALAŽA)
Plastic bottles (HDPE) containing 120 tablets.
Plastične bočice (HDPE) koje sadrže 120 tableta.
Plastic box containing 10, 20 or 50 bottles Not all pack sizes may be marketed.
Plastična kutija koja sadrži 10, 20 ili 50 bočica Ne moraju sve veličine pakovanja biti u prometu.
Plastic box containing 25 vials of lyophilisate and 25 vials of solvent.
Plastična kutija sadržava 25 bočica liofilizata i 25 bočica otapala.
Plastic box containing 25 vials.
Plastična kutija sadržava 25 bočica liofilizata i 25 bočica otapala.
Plastic box containing 5 vials of 1 dose of lyophilisate and 5 vials of solvent.
Plastične kutije koje sadrže 5 bočica od 1 doze liofilizata i 5 bočica otapala.
Plastic box containing 50 vials of lyophilisate and 50 vials of solvent.
Plastična kutija sadržava 50 bočica liofilizata i 50 bočica otapala.
Plastic box containing 50 vials.
Plastična kutija sadržava 50 bočica liofilizata i 50 bočica otapala.
Plastic box with 10 glass vials of 1 ml (1 dose).
Plastična kutija sa 10 staklenih bočica od 1 ml ( 1 doza).
Plastic box with 10 glass vials.
Plastična kutija sa 10 staklenih bočica.
Plastic box with 25 x 1 dose vial of vaccine and 25 x 1 ml vial of solvent.
Plastična kutija s bočicom od 25 x 1 dozom cjepiva i 25 bočica s 1 ml otapala.
Plastic box with 25 x 1 dose vial of vaccine and 25 x 1 ml vial of solvent.
Plastična kutija s bočicom od 25 x 1 dozom cjepiva i 25 x 1 ml otapala.
Plastic box with 5 or 10 pre-filled syringes of 1 ml (1 dose).
Plastična kutija sa 5 ili 10 napunjenih šprica od 1 ml ( 1 doze).
Plastic box with 5 or 10 pre-filled syringes.
Plastična kutija sa 5 ili 10 napunjenih šprica.
Plastic box with 5 x 1 dose of vaccine including 5 x 1 ml solvent vials (glass) Plastic box with 25 x 1 dose of vaccine including 25 x 1 ml solvent vials (glass) Cardboard box with 10 x 50 doses of vaccine
Plastična kutija s 5 x 1 dozom cjepiva i 5x1 ml (staklenih) bočica otapala Plastična kutija s 25 x 1 dozom cjepiva i 25x1 ml (staklenih) bočica otapala Kartonska kutija s 10 x 50 dozom cjepiva
Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
Plastična kutija s bočicom od 5 x 1 dozom cjepiva i 5 bočica s 1 ml otapala.
Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
Plastična kutija s bočicom od 5 x 1 dozom cjepiva i 5 x 1 ml otapala.
PLASTIC JAR and LEAD CONTAINER
PLASTIČNA POSUDA i OLOVNI SPREMNIK
Plastic LDPE bottle of 30 ml (1,000 doses) with butyl rubber stopper and sealed with an aluminium cap.
Plastična LDPE boca od 30 ml (1000 doza) s butil gumenim čepom zapečaćena aluminijskim zatvaračem.
Plastic oral syringe 10 mg/2 ml
Plastična štrcaljka za usta 10 mg/2 ml
Plastic oral syringe 2.5 mg/0.5 ml
Plastična štrcaljka za usta 2,5 mg/0,5 ml
Plastic oral syringe 5 mg/1 ml
Plastična štrcaljka za usta 5 mg/1 ml
Plastic oral syringe 7.5 mg/1.5 ml
Plastična štrcaljka za usta 7,5 mg/1,5 ml
Plastic Tube Label 10 mg /2 ml
Naljepnica na plastičnoj tubi 10 mg/2 ml
Plastic Tube Label 2.5 mg /0.5 ml
Naljepnica na plastičnoj tubi 2,5 mg/0,5 ml
Plastic Tube Label 5 mg /1 ml
Naljepnica na plastičnoj tubi 5 mg/1 ml
Plastic Tube Label 7.5 mg /1.5 ml
Naljepnica na plastičnoj tubi 7,5 mg/1,5 ml
platelet < 50 x 109/L
ili trombociti < 50 x 109/l
Platelet aggregation and bleeding time gradually returned to baseline values, generally within days after treatment was discontinued.
Agregacija trombocita i vrijeme krvarenja postupno se vraćaju na početne vrijednosti, obično unutar 5 dana nakon prekida uzimanja lijeka.
Platelet aggregation inhibitors should be discontinued as suggested by the manufacturer’s prescribing information.
Inhibitori agregacije trombocita moraju se prestati koristiti kao što se preporučuje u uputama proizvođača.
PLATELET AGGREGGATION INHIBITORS
INHIBITORI AGREGACIJE TROMBOCITA
Platelet and red blood cell support, as well as the use of growth factors such as Granulocyte-colony stimulating factor (G-CSF), should be employed as medically indicated.
U slučaju kliničke indikacije potrebne su transfuzije eritrocita i trombocita kao i primjena čimbenika rasta kao što je faktor stimulacije kolonije granulocita (G-CSF).
Platelet and white blood cell (WBC) monitoring
Praćenje trombocita i leukocita
platelet count
broj trombocita
platelet count
Normalizacija broja trombocita
Platelet Count
Trombociti
Platelet count (cells/mm3)
(stanice/mm3)
Platelet count (x 109/l)
Broj trombocita (x 109/l)
Platelet Count (x109/L)
Broj trombocita (x109/l)
Platelet count < 10 x 109/L or evidence of bleeding with thrombocytopenia (see section 4.4)
Broj trombocita < 10 x 109/l ili dokaz krvarenja uz trombocitopeniju (vidjeti dio 4.4)
Platelet count < 25,000/mm3 Hemoglobin < 8 g/dl
< 25 000/mm3 Hemoglobin < 8 g/dl
Platelet count <25 x 109/l
Broj trombocita <25 x 109/l
Platelet count >75,000/microlitre
Broj trombocita > 75 000/mikrolitra
Platelet count abnormal
Abnormalan broj trombocita
Platelet count decreased
manjen broj krvnih pločica
Platelet count decreased
manjen broj trombocita
Platelet count decreased
manjenje broja trombocita
Platelet count decreased
Smanjen broj trombocita
Platelet count decreased
Snižen broj trombocita
Platelet count decreased
sniženi broj trombocita
Platelet count decreased Heart rate increased Haematocrit decreased Haemoglobin decreased
niženi broj trombocita, povećan broj srčanih otkucaja, snižen hematokrit, snižen hemoglobin
Platelet count decreased Heart rate increased Haematocrit decreased Haemoglobin decreased
niženi broj trombocita, povećan broj srčanih otkucaja, snižen hematokrit, snižen hemoglobin,
Platelet count decreased Weight increased
sniženi broj trombocita povećanje težine
Platelet count decreased, Red blood cell count decreased, International normalised ratio increased c
snižen broj trombocita, snižen broj crvenih krvnih stanica, povišen međunarodni normalizirani omjer c
Platelet count decreasedh
Smanjen broj trombocitah
Platelet count increased
Povećanje broja trombocita
Platelet count monitoring
Praćenje broja trombocita
Platelet count normalization
Normalizacija broja trombocita
Platelet count return to ≥50 x 109/l
Oporavak broja trombocita na
Platelet count should be monitored at least weekly for 2 to 3 weeks when eltrombopag is co- administered with ciclosporin.
Potrebno je praćenje broja trombocita najmanje jednom tjedno tijekom 2 do 3 tjedna kada se eltrombopag istodobno primjenjuje s ciklosporinom.
platelet counts <100,000/mm3 (monotherapy) and <150,000/mm3 (consolidation treatment)
bolesnicima s brojem trombocita < 100 000/mm3 (monoterapija) i < 150 000/mm3 (konsolidacijska terapija)
Platelet counts > 75,000/µl should be avoided.
Broj trombocita > 75 000/µl treba izbjegavati.
Platelet counts above the normal range present a risk for thrombotic/thromboembolic complications.
Broj trombocita viši od normalnih vrijednosti predstavlja rizik za trombotičke/tromboembolijske komplikacije.
Platelet counts below 100 x 109/l were observed in 7% of patients treated with MIRCERA and 4% of patients treated with other ESAs.
Broj trombocita niži od 100 x 109/l opažen je u 7% bolesnika liječenih lijekom MIRCERA i 4% bolesnika liječenih drugim LSE.
Platelet counts below 30 million per millilitre are considered to put ITP patients at risk of bleeding, while normal counts are between 150 and 400 million per millilitre.
Smatra se da su bolesnici koji boluju od ITP-a i čiji je broj trombocita ispod 30 milijuna po mililitru izloženi riziku od krvarenja, dok se normalnim brojem smatra između 150 i 400 milijuna trombocita po mililitru.
Platelet counts should be assessed weekly until a stable platelet count (≥ 50 x 109/l for at least 4 weeks without dose adjustment) has been achieved.
Broj trombocita mora se provjeravati svaki tjedan, sve dok ne postane stabilan (Tr ≥ 50 x 109/l tijekom najmanje 4 tjedna bez prilagodbe doze).
Platelet counts should be ≥ 70 x 109/l and the absolute neutrophils count should be ≥ 1.0 x 109/l
Broj trombocita mora biti ≥ 70 x 109/l, a apsolutni broj neutrofila mora biti ≥ 1,0 x 109/l
Platelet counts should be ≥ 70 x 109/l and the absolute neutrophils count should be ≥ 1.0 x 109/l
Broj trombocita mora biti ≥ 70 x 109/l, a apsolutni broj neutrofila mora biti ≥ 1,0 x 109/l.
Platelet counts should be ≥ 75,000 cells/μL in patients with bone marrow infiltration or splenic sequestration
Broj trombocita mora biti ≥ 75 000 stanica/μL u bolesnika s infiltracijom koštane srži i sa sekvestracijom u slezeni
Platelet counts should therefore be monitored closely.
Broj trombocita treba stoga pomno nadzirati.
Platelet counts should therefore be monitored closely.
Stoga je broj trombocita potrebno pažljivo pratiti.
Platelet counts should therefore be monitored closely.
Zbog toga treba pažljivo nadzirati broj trombocita.
Platelet counts ≤100x109/l at baseline to >50% increase or >100x109/l post baseline
Broj trombocita ≤ 100x109/l za početne vrijednosti do > 50% povećanje ili
Platelet engraftment occurred at a median of 9 (range, 1-16) days after allo-HCT.
Primanje presatka trombocita dogodilo se u medijanu od 9 (raspon 1 – 16) dana nakon alogenog HCT-a.
Platelet function is restored within 60 minutes of stopping the infusion.
Funkcija trombocita se ponovno uspostavlja unutar 60 minuta od prekida infuzije.
Platelet levels should be monitored regularly and the dose of Revolade should be adjusted if needed.
Razine trombocita trebalo bi redovito nadzirati a dozu lijeka Revolade po potrebi prilagođavati.
Platelet poor plasma had no effect on bleeding times or platelet aggregation. (See section 4.4.)
Plazma siromašna trombocitima nije utjecala na vremena krvarenja ni na agregaciju trombocita (vidjeti dio 4.4.).
Platelet studies
Ispitivanja učinaka na trombocite
Platelet transfusion is unlikely to be of clinical benefit in patients with bleeding (see section 4.4).
Malo je vjerojatno da će transfuzija tombocita biti od kliničke koristi u bolesnika sa krvarenjem (vidjeti dio 4.4).
Platelet transfusions were given to 10 % of patients in 4 % of courses.
Transfuzije trombocita primijenjene su u 10% bolesnika u 4% ciklusa.
Platelets
Broj trombocita
Platelets
trombociti
Platelets (x 109/l)
Trombociti (x 109/L)
Platelets < 25 x 109/l thrombocytopenia
Broj trombocita < 25 x 109/l trombocitopenija
Platelets < 50 x 109/l thrombocytopenia complicated by haemorrhage or requiring blood or platelet transfusion
Broj trombocita < 50 x 109/l trombocitopenija komplicirana krvarenjem ili zahtijeva transfuziju krvi ili trombocita
Platelets < 50×109/L
trombociti < 50×109/l
Platelets < 80,000/mm3 Haemoglobin < 4.5 g/dl
Trombociti < 80 000/mm3 Hemoglobin < 4,5 g/dl
Platelets are very small structures in the blood which clump together during blood clotting.
Trombociti su vrlo mala krvna tjelešca tzv. krvne pločice, koje se nakupljaju tijekom zgrušavanja krvi.
Platelets decrease
snižen broj trombocita
Platelets Decreased
snižen broj neutrofila
Platelets decreased
snižen broj trombocita
Platelets form an important part of the clotting process and a reduction in their numbers may cause unwanted bleeding and bruising.
Trombociti igraju važnu ulogu u procesu zgrušavanja i smanjen broj trombocita može uzrokovati neželjeno krvarenje i stvaranje hematoma.
Platelets were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle.
Trombociti su bili najniži 11. dana svakog ciklusa liječenja bortezomibom i obično su se povukli do početnog stanja do sljedećeg ciklusa.
Platelets were lowest at Day 11 of each cycle of bortezomib treatment and typically recovered to baseline by the next cycle.
Trombociti su bili najniži na 11. dan svakog ciklusa liječenja bortezomibom i obično su se do sljedećeg ciklusa vratili na početno stanje.